Overview

COL Immunotherapy Before Radiochimio + Ipilimumab

Status:
Active, not recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, single arm pilot study evaluating the biological impact of "Nivolumab + Ipilimumab" in patients with cervical squamous cell carcinoma requiring RT-CT as initial therapy

Phase:

N/A

Details

Lead Sponsor:

ARCAGY/ GINECO GROUP

Collaborator:

Bristol-Myers Squibb

Treatments:

Ipilimumab
Nivolumab